A CASE REPORT OF THE USE TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE ARTHRITIS WITH PULMONARY INVOLVEMENT AND MACROPHAGE ACTIVATION SYNDROME
The paper describes a patient with refractory systemic juvenile arthritis treated with tocilizumab (TCZ). Specific features of therapeutic response in real clinical practice, aspects of individual TCZ safety in the development of macrophage activation syndrome and concurrent therapy are discussed.
Main Authors: | M. I. Kaleda, I. P. Nikishina, S. R. Rodionovskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2015-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2117 |
Similar Items
-
EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01) -
A CLINICAL CASE OF SYSTEMIC JUVENILE ARTHRITIS COMPLICATED BY RECURRENT MACROPHAGE ACTIVATION SYNDROME AND CHRONIC OSTEOMYELITIS OF THE CLAVICLE
by: M. I. Kaleda, et al.
Published: (2018-03-01) -
Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study
by: M. I. Kaleda, et al.
Published: (2019-05-01) -
THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01) -
Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
by: Kessler Elizabeth A, et al.
Published: (2012-08-01)